40 pharma firms interested in producing anti COVID drug 2-DG: DRDO tells Madras HC

Published On 2021-06-26 06:42 GMT | Update On 2021-06-26 06:42 GMT

Chennai: The Madras High Court was told by the Defence Research and Development Organisation (DRDO) on Friday that 40 pharmaceutical firms had shown interest in manufacturing 2-deoxy-D-Glucose (2-DG) an adjunct drug used in COVID-19 treatment.

This comes in response to a Public Interest Litigation filed by D. Saravanan, a Chennai citizen, who claimed that the Defence Research and Development Organisation (DRDO) had granted a licence to Dr Reddy's Laboratories in Hyderabad alone to manufacture the oral powder at a cost of Rs 990 for a 2.34-gram sachet.

The anti-COVID-19 therapeutic application of 2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based Dr Reddy''s Laboratories.

The petitioner complained that DRDO had given licence to Dr Reddys Laboratories in Hyderabad alone for producing the oral powder at a cost of Rs 990 per sachet of 2.34 grams and not to any other pharma company in the country.

Additional Solicitor General R Sankaranarayanan appearing for DRDO made the submission before the second bench of Justices N Kirubakaran and T V Tamilselvi.

Sankaranarayanan said DRDO had invited Expression of Interest to produce the drug and so far 40 pharmaceutical companies had shown interest. The DRDO was highly capable of ensuring that the drug is manufactured in large quantities within the shortest possible time. It had fixed June 17 as the last date for submitting an Expression of Interest to manufacture the drug and 40 companies had responded.

The court took note of a submission by a litigant that the DRDO''s drug was very effective and that a woman COVID-19 patient, with comorbidities had a "magical cure" after being administered with 30 sachets of the drug. He said the doctor who treated the patient was also ready to vouch for its efficacy and the bench recorded its appreciation to the doctor concerned.

As per a recent PTI report, the judges reserved their verdict after attentively hearing arguments and instructed the ASG to circulate all relevant documents regarding the case.

Article Source : With agency inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

40 pharma firms interested in producing anti COVID drug 2-DG: DRDO tells Madras HC

Similar News

Abbott to Conduct BE Study for Carbimazole 15 mg, Trial Waiver Granted In India

Pfizer Gets Expert Panel Nod to Update Etanercept Pre-Filled Injection Label

Marksans Pharma gets USFDA nod for heartburn drug

Zydus Lifesciences gets NOC from Health Canada for ZDS-Varenicline tablets

CDSCO Committee Asks Elevate Scientific To Prove Back Pain Gel In Indian Trial

Dr Reddy's Gets CDSCO Panel Approval To Begin Phase III Trial of Tapinarof Cream

No Ban on Paracetamol, Says Govt; 156 Drug Combos Axed Over Safety Concerns

Lincoln Pharma re-appoints Mahendra G Patel as MD